{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:37:45Z","timestamp":1787888265945,"version":"build-2784847793"},"reference-count":48,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"GSK","award":["BEL110751"],"award-info":[{"award-number":["BEL110751"]}]},{"name":"GSK","award":["BEL110752"],"award-info":[{"award-number":["BEL110752"]}]},{"name":"GSK","award":["BEL112341"],"award-info":[{"award-number":["BEL112341"]}]},{"name":"GSK","award":["BEL113750"],"award-info":[{"award-number":["BEL113750"]}]},{"name":"GSK","award":["BEL115471"],"award-info":[{"award-number":["BEL115471"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the effects of belimumab (BEL) on systemic lupus erythematosus (SLE) mucocutaneous and vasculitis manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc, integrated Belimumab Summary of Lupus Efficacy (Be-SLE) analysis pooled data from five international Phase 3, randomized, placebo (PBO)-controlled BEL trials (BLISS-52 [NCT00424476; conducted in 2007\u20132009], BLISS-76 [NCT00410384; 2007\u20132009], BLISS-SC [NCT01484496; 2011\u20132015], North East Asia [NCT01345253; 2011\u20132015], EMBRACE [NCT01632241; 2013\u20132018]). Adults with active SLE and Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score \u22656 (BLISS-52, BLISS-76) or \u22658 (BLISS-SC, North East Asia, EMBRACE), randomized to BEL (10\u00a0mg\/kg\/month intravenously or 200\u00a0mg\/week subcutaneously) or PBO, plus standard therapy (ST) were included. Mucocutaneous and vasculitis manifestations (listed below) were measured (baseline and every 4\u00a0weeks) for 52\u00a0weeks using SELENA-SLEDAI and British Isles Lupus Assessment Group (BILAG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 3086 patients (BEL,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1869; PBO,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1217), 85% (BEL and PBO) by SELENA-SLEDAI and 58% (BEL) and 62% (PBO) by BILAG (moderate or severe activity) had mucocutaneous manifestations, and &lt;10% had vasculitis at baseline. At Week 52, significantly more BEL-treated than PBO-treated patients demonstrated improvements in SELENA-SLEDAI (59% vs 49%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .0001) and BILAG (54% vs 43%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; .0001) mucocutaneous domains. Significant differences between-treatment favored BEL at Week 52 for resolution of all SELENA-SLEDAI items (vasculitis, rash, alopecia, and mucosal ulcers), and nine of 20 BILAG items (mild maculopapular eruption, localized active discoid lesions, mild alopecia, small mucosal ulceration, malar erythema, subcutaneous nodules, swollen fingers, major cutaneous vasculitis including ulcers, and minor cutaneous vasculitis).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with SLE treated with BEL plus ST experienced significant improvements in most mucocutaneous and vasculitis manifestations compared with patients receiving PBO plus ST. These data provide additional support for the use of BEL in SLE and show that it is associated with skin improvements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09612033251337130","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T06:42:43Z","timestamp":1746427363000},"page":"666-678","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis"],"prefix":"10.1177","volume":"34","author":[{"given":"Susan","family":"Manzi","sequence":"first","affiliation":[{"name":"Allegheny Health Network"},{"name":", Lupus Center of Excellence"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"S\u00e1nchez-Guerrero","sequence":"additional","affiliation":[{"name":"University of Toronto"},{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-443X","authenticated-orcid":false,"given":"Naoto","family":"Yokogawa","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Tama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Wenzel","sequence":"additional","affiliation":[{"name":"University Hospital of Bonn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine C","family":"Ocran-Appiah","sequence":"additional","affiliation":[{"name":"GSK"},{"name":"Respiratory and Immunology Clinical Research and Early Programs"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia HN","family":"Harris","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-6024","authenticated-orcid":false,"given":"Munther","family":"Khamashta","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Rubin","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Lynn Fox","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A","family":"Levy","sequence":"additional","affiliation":[{"name":"GSK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P","family":"Werth","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine"},{"name":"Corporal Michael J. Crescenz VAMC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.05.006"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0480-7"},{"key":"e_1_3_7_4_2","first-page":"834291","article-title":"Cutaneous manifestations of systemic lupus erythematosus","volume":"2012","author":"Uva L","year":"2012","unstructured":"Uva L, Miguel D, Pinheiro C, et al. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis 2012; 2012: 834291.","journal-title":"Autoimmune Dis"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2018.07.003"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000444"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41480"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120399680411281"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.10.756"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh624"},{"issue":"259","key":"e_1_3_7_12_2","first-page":"927","article-title":"Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG)","volume":"69","author":"Symmons DP","year":"1988","unstructured":"Symmons DP, Coppock JS, Bacon PA, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988; 69(259): 927\u2013937.","journal-title":"Q J Med"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev387"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23889.x"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41253"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316682097"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2019.12.004"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.1772"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15312"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06552.x"},{"issue":"3","key":"e_1_3_7_22_2","first-page":"Cd007478","article-title":"Interventions for cutaneous disease in systemic lupus erythematosus","volume":"3","author":"Hannon CW","year":"2021","unstructured":"Hannon CW, McCourt C, Lima HC, et al. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev 2021; 3(3): Cd007478.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5485"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.09.017"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25058"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40049"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00317-9"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38010"},{"key":"e_1_3_7_30_2","unstructured":"GSK. China\u2019s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis. 2022. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/china-s-national-medical-products-administration-approves-benlysta-belimumab-for-adult-patients-with-active-lupus-nephritis\/ (accessed 8 August 2024)."},{"key":"e_1_3_7_31_2","unstructured":"GSK. Benlysta prescribing information. 2024. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MG-IFU.PDF (accessed 1 August 2024)"},{"key":"e_1_3_7_32_2","unstructured":"Benlysta EMA. Summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf (accessed 8 August 2024)."},{"key":"e_1_3_7_33_2","unstructured":"GSK. GSK receives approval for Benlysta in Japan for the treatment of systemic lupus erythematosus. 2017. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-receives-approval-for-benlysta-in-japan-for-the-treatment-of-systemic-lupus-erythematosus\/ (accessed 1 August 2024)."},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41900"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.34400"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13419"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.11.007"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200831"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22971"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1630897"},{"issue":"2","key":"e_1_3_7_44_2","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman DD","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29(2): 288\u2013291.","journal-title":"J Rheumatol"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06268-y"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1037408"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040691"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0702-6"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251337130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033251337130","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251337130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:28:54Z","timestamp":1777678134000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033251337130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/09612033251337130"],"URL":"https:\/\/doi.org\/10.1177\/09612033251337130","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}